Discover the transformation of a complex assessment challenge into a competitive advantage. Our electronic CDRS-R doesn't just digitize the scale—it embeds clinical expertise, automates quality controls, and guides raters through every step to ensure consistent, reliable data.

The future of psychedelic medicine depends on applying strict scientific standards, using evidence-based approaches to manage the inherent challenges of studying these consciousness-altering compounds.

Learn about frequent administration and scoring errors in MMSE and ADAS-Cog assessments during Alzheimer's trials and how data surveillance and targeted rater training can improve cognitive testing.

Examine challenges and solutions in epilepsy trials, including electronic diaries, placebo response training, and integrated cognitive assessments, transforming research approaches.

Discover how this validated 7-minute cognitive assessment transforms CNS trials through precise patient stratification, objective attention measurements, and enhanced signal detection.

A pharma company used Signant Health's RTSM solution in a Phase 2 schizophrenia trial to ensure drug availability, maintain study balance, prevent duplicate allocations, and manage returns and destruction of unused drugs.

Signant Biotech optimized technology for an emerging biopharmaceutical's Phase 2 COVID treatment trial in critically ill patients, minimizing paper data risks and streamlining consent and data management across multiple sites and solutions.

A Japan-based biotechnology company leveraged Signant SmartSignals® GxP Inventory, which improved visibility, reduced risks and costs, and optimized operations in this case study.

Signant’s SmartSignals® RTSM solution helped an innovative biopharmaceutical company secure an FDA Orphan Drug designation for its cardiomyopathy drug.

Explore how these integrated solutions helped an emerging biopharma to implement a plan for study build and migration with minimal disruption to sites.